Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526000 · ClinicalTrials.gov registry record
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 326
- Enrollment target
NCT06526000: Completed study, sponsored by Novartis.
NCT06526000 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 326 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06526000 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 326 participants
- Enrollment target
Study Summary
This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20 monoclonal antibody treatment in clinical practice. The index date was defined as the date of anti-CD20 drug initiation during the study period. The baseline period was defined as 12 months prior to the index date.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2024-02-28 |
What the finished NCT06526000 record still lists
NCT06526000 is an observational study that tracks outcomes without assigning an intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06526000 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06526000 about?
NCT06526000 is a clinical study titled "Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies". This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20 monoclonal antibody treatment in clinical practice. The index date was defi...
What is the current status of trial NCT06526000?
This trial is currently completed. The enrollment target is 326 participants. The study started on 2022-10-11. Estimated completion is 2024-02-28.
Who is sponsoring clinical trial NCT06526000?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06410144 · 326 participants · NA
Chronic Kidney Disease-Education (CKD-EDU)
- NCT06586619 · 326 participants · NA
A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV
- NCT07040566 · 326 participants · Phase 2
A Trial of Varenicline for E-cigarette Cessation
- NCT07165860 · 326 participants · NA
Clinical Trial to Reduce Perinatal Intimate Partner Violence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI